abivax_site.png
BioMedTech Press Release

Abivax's drug-candidate ABX196, shows good tolerability and promising signals of clinical benefit in liver cancer

"We are excited to observe a good safety profile as well as signals of clinical benefit in liver cancer patients treated with a combination of ABX196 and the checkpoint inhibitor nivolumab. The selection of the results of this phase 1/2 trial for a poster presentation at the ASCO GI Cancers Symposium 2022 validates these first promising data generated in the dose escalation phase of the study." Darren Sigal, M.D., Scripps MD Anderson Cancer Center

  • ABX196 is Abivax's second compound in clinical development after lead drug-candidate ABX464

  • ABX196 was well tolerated and demonstrated promising signals of clinical benefit in heavily pretreated hepatocellular cancer patients

  • ABX196 phase 1/2 study results were selected for a presentation at the 2022 ASCO GI Cancers Symposium

  • Detailed data of the abstract submitted at the ASCO GI Cancers Symposium will be released as of January 18, 2022, in accordance with the official ASCO embargo policy